Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

ANTARES PHARMA, INC.

(ATRS)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Insider Trends: Antares Pharma Insider Receives Stock Award Uses Portion to Pay Taxes, Slowing 90-Day Buy Trend

06/14/2021 | 06:23pm EDT


© MT Newswires 2021
All news about ANTARES PHARMA, INC.
07/22ANTARES PHARMA : Gets US FDA OK to Start Trial of ATRS-1902 in Acute Adrenal Ins..
MT
07/22ANTARES PHARMA : Announces FDA Acceptance of IND Application for ATRS 1902 For A..
PU
07/22Antares Pharma Announces FDA Acceptance of IND Application for ATRS-1902 for ..
GL
07/22Antares Pharma, Inc Announces FDA Acceptance of IND Application for ATRS-1902..
CI
07/16ANTARES PHARMA : Truist Securities Initiates Coverage on Antares Pharma With Buy..
MT
07/09INSIDER TRENDS : Insider Disposition Eases Back 90-Day Buy Trend at Antares Phar..
MT
07/07Antares Pharma to Present at the Ladenburg Thalmann Annual Healthcare Confere..
GL
06/28ANTARES PHARMA : ' Swiss Partner Idorsia Kicks Off Late-Stage Study for Selatogr..
MT
06/28Antares Pharma Announces Partner Idorsia Initiates the Phase 3 Study With Sel..
GL
06/28Idorsia to trial self-injection drug for heart attack victims
RE
More news
Financials (USD)
Sales 2021 189 M - -
Net income 2021 20,3 M - -
Net Debt 2021 - - -
P/E ratio 2021 37,6x
Yield 2021 -
Capitalization 734 M 734 M -
Capi. / Sales 2021 3,89x
Capi. / Sales 2022 3,15x
Nbr of Employees 185
Free-Float 97,8%
Chart ANTARES PHARMA, INC.
Duration : Period :
Antares Pharma, Inc. Technical Analysis Chart | ATRS | US0366421065 | MarketScreener
Technical analysis trends ANTARES PHARMA, INC.
Short TermMid-TermLong Term
TrendsNeutralNeutralBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 7
Last Close Price 4,35 $
Average target price 6,57 $
Spread / Average Target 51,1%
EPS Revisions
Managers and Directors
Robert F. Apple President, Chief Executive Officer & Director
Fred M. Powell Chief Financial Officer & Executive Vice President
Leonard S. Jacob Chairman
Jonathan S. Jaffe Vice President-Clinical & Medical Affairs
Peter C. Richardson Chief Medical Officer & Executive VP-Research
Sector and Competitors
1st jan.Capi. (M$)
ANTARES PHARMA, INC.9.02%733
ABBOTT LABORATORIES10.33%200 283
MEDTRONIC PLC9.73%168 081
BECTON, DICKINSON AND COMPANY0.34%70 145
HOYA CORPORATION3.33%50 251
ALIGN TECHNOLOGY, INC.19.44%48 667